Non-neoplastic advanced lung disease / edited by Janet R. Maurer.

Format:

Book

Contributor:

Maurer, Janet R.

Series:

Lung biology in health and disease ; v. 176.

Lung biology in health and disease ; v. 176

Language:

English

Subjects (All):

Lungs--Diseases.

Lungs.

Lung Diseases.

Medical Subjects:

Lung Diseases.

Physical Description:

xix, 817 pages : illustrations ; 24 cm.

Place of Publication:

New York : Marcel Dekker, [2003]

Contents:

Part 1 Pathology of Advanced Lung Disease

1. Pathology of Advanced Obstructive Lung Disease: Emphysema, Chronic Bronchitis, Bronchiolitis Obliterans, Bronchiectasis / Joseph F. Tomashefski 1

II. Emphysema 1

III. Chronic Bronchitis 10

IV. Bronchiolitis Obliterans 12

V. Bronchiectasis 17

2. Pathology of Advanced Interstitial Diseases: Pulmonary Fibrosis, Sarcoidosis, Pulmonary Histiocytosis X, Autoimmune Pulmonary Disease, and Lymphangioleiomyomatosis / Carol F. Farver 29

II. Pulmonary Fibrosis 29

III. Sarcoidosis 31

IV. Pulmonary Histiocytosis X (Eosinophilic Granuloma, Langerhans Cell Granulomatosis of the Lung) 36

V. Autoimmune Pulmonary Disease 39

VI. Lymphangioleiomyomatosis 44

3. Pathology of Advanced Pulmonary Vascular Disease / J. Michael Kay 59

II. Systemic-to-Pulmonary Shunts 63

III. Primary Pulmonary Arterial Hypertension 76

IV. Chronic Pulmonary Thrombotic and/or Embolic Disease 82

V. Pulmonary Veno-occlusive Disease 90

VI. Pulmonary Capillary Hemangiomatosis 100

VII. Lung Biopsy in Advanced Pulmonary Vascular Disease 104

VIII. Risks and Benefits of Lung Biopsy 106

Part 2 Rest and Exercise Physiology in Advanced Lung Disease

4. Management of Advanced Advanced Chronic Obstructive Pulmonary Disease / Denis E. O'Donnell, Nha Voduc 117

II. Pathophysiology of Exercise Intolerance in COPD 119

III. Assessment of the Dyspneic Patient 127

IV. Management 134

V. Oxygen Therapy 150

VI. Case Summary 153

VII. Adjunctive Therapies 155

VIII. Management of Acute Exacerbation of COPD 160

5. Role of Physiological Assessment in Advanced Interstitial Lung Disease / Idelle M. Weisman, Joseph P. Lynch III, Fernando J. Martinez 179

I. Physiological Abnormalities 180

II. Clinical Applications 198

III. Idiopathic Pulmonary Fibrosis 200

IV. Collagen Vascular Diseases 205

V. Rheumatoid Arthritis 212

VI. Polymyositis and Dermatomyositis 215

VII. Overlap Syndrome and Mixed Connective Tissue Disease 215

VIII. Sjogren's Syndrome 216

IX. Sarcoidosis 216

X. Pulmonary Function Tests in Sarcoidosis 217

XI. Langerhans Cell Histiocytosis (Pulmonary Eosinophilic Granuloma) 221

6. Pulmonary Vascular Disease / Sean P. Gaine 249

II. Physiology of the Normal Pulmonary Vascular Bed 249

III. Pathophysiology of the Pulmonary Vascular Bed 253

IV. Physiology of Exercise in Pulmonary Vascular Disease 255

Part 3 Medical Management

7. Management of Nonbronchiectatic Chronic Obstructive Pulmonary Disease / Fernando J. Martinez, Steven E. Gay, Kevin R. Flaherty 271

I. Goals of Therapy 272

II. Assessing and Monitoring Disease 273

III. Medical Management of the Stable Patient with COPD 277

IV. Medical Management of the COPD Patient During an Exacerbation 315

8. Management of Bronchiectasis and Cystic Fibrosis / Vivek N. Ahya, Gregory Tino, Stanley B. Fiel 339

II. Bronchiectasis: An Introduction 340

III. Pathology 340

IV. Pathophysiology 340

V. Etiology 341

VI. Focal Bronchiectasis 342

VII. Diffuse Bronchiectasis 342

VIII. Clinical Features 346

IX. Cystic Fibrosis: An Introduction 356

X. Pathogenesis 357

XI. Current Medical Management of CF 360

XII. Medical Management of CF Airways Disease 364

XIII. The Future 375

9. Pulmonary Interstitial Disease: Idiopathic, Autoimmune, and Drug-Related / Edward Moloney, Jim J. Egan 387

II. Interstitial Lung Disease in Connective Tissue Disorders 391

III. Drug-Induced Pulmonary Disease 393

IV. Drug Therapy for UIP/IPF 396

V. Management of Patients with Advanced Pulmonary Fibrosis 402

10. Sarcoidosis, Lymphangioleiomyomatosis, and Histiocytosis / Francis X. McCormack, Fortune O. Alabi 415

I. Sarcoidosis 415

II. Lymphangioleiomyomatosis 429

III. Langerhans Cell Histocytosis 440

11. Medical Management of Pulmonary Vascular Disease / Allison C. Widlitz, Robyn J. Barst 463

II. General Measures 465

III. Anticoagulation 467

IV. Oxygen 467

V. Cardiac Glycosides and Diuretics 468

VI. Vasodilators 468

VII. Calcium Channel Blockers 469

VIII. Prostaglandins 470

IX. Endothelin Receptor Antagonists 473

X. Nitric Oxide 474

XI. The Future 475

Part 4 Surgical Management

12. Lung Volume Reduction Surgery / Gerald J. Criner, Francis C. Cordova 481

II. Pathophysiological Basis for Lung Volume Reduction Surgery 482

III. History of Lung Volume Reduction Surgery 484

IV. Outcome of Lung Volume Reduction Surgery 487

V. Techniques of Lung Volume Reduction Surgery 508

VI. Physiological Mechanisms of Improvement with Lung Volume Reduction Surgery 509

VII. Complications of Lung Volume Reduction Surgery 515

VIII. Patient Selection 516

13. Pulmonary Thromboendarterectomy / William R. Auger, Peter F. Fedullo, Kim M. Kerr, David P. Kapelanski, Stuart W. Jamieson 541

II. Historical Perspective 542

III. Natural History 544

IV. Clinical Presentation 545

V. Diagnostic Evaluation 547

VI. Pulmonary Thromboendartectomy 553

VII. Postoperative Care 560

VIII. Outcome Following Pulmonary Thromboendartectomy 561

IX. Future Directions 564

14. Lung Transplantation / Adaani E. Frost 571

I. History 571

II. Indications 572

III. Surgical Options 579

IV. Complications 580

V. Outcomes 583

Part 5 Incidence and Management of Medical Comorbidities

15. Comorbidities in Advanced Lung Disease / Janet R. Maurer 587

II. Impact of Comorbidities 587

III. Cardiac and Vascular Comorbidities 589

IV. Pulmonary Embolism 595

V. Gastroesophageal Reflux Disease 596

VI. Cancer 597

VII. Cognitive Functioning 599

16. Osteoporosis and Metabolic Bone Disease and Endocrine Abnormalities / Robert M. Aris, Sue A. Brown, David A. Ontjes 607

II. Osteoporosis 608

III. Osteoporosis: Presentation 611

IV. Osteoporosis: Diagnostic Approach 612

V. Osteoporosis: Management and Therapy 612

VI. Osteoporosis in Chronic Obstructive Pulmonary Disease 614

VII. Osteoporosis in Asthma 617

VIII. Osteoporosis in Cystic Fibrosis 618

IX. Osteoporosis in Sarcoidosis 620

X. Osteoporosis in Lymphangioleiomyomatosis 620

XI. Endocrine Abnormalities 620

XII. Langerhans Cell Histiocytosis (Eosinophilic Granuloma) 625

XIII. Wegener's Granulomatosis 626

XIV. Bronchiolitis Obliterans Organizing Pneumonia 627

XV. Pulmonary Hypertension 627

XVI. Hypogonadism 627

17. Cachexia in Chronic Obstructive Pulmonary Disease / Eva C. Creutzberg, Annemie M. W. J. Schols, Emiel F. M. Wouters 637

II. Prevalence of Cachexia in COPD 637

III. Underlying Factors of Cachexia in COPD 638

IV. Consequences of Cachexia in COPD 644

V. Treatment of Cachexia in COPD 646

Part 6 Psychosocial Management and Quality of Life

18. Anxiety, Depression, and Coping Skills / Susan E. Abbey 661

II. Enhancing Coping Strategies in Distressed Patients 662

III. Anxiety and Anxiety Disorders 667

IV. Panic Attacks and Panic Disorder 668

V. Generalized Anxiety Disorder 669

VI. Adjustment Disorder with Anxious Mood 670

VII. Posttraumatic Stress Disorder 670

VIII. Management 671

IX. Depression and Depressive Disorders 676

19. Measurement of Health Status in Advanced Respiratory Disease / Donald A. Mahler, Paul W. Jones 685

I. What Is Health-Related Quality of Life? What Is Health Status? 685

II. Measurement Criteria 686

III. Types of Health Status Questionnaires 687

IV. Minimal Important Difference 695

V. Clinical Applications 697

20. Traveling with Supplemental Oxygen for Patients with Chronic Lung Disease / Loutfi Sami Aboussouan, James K.

Stoller 711

II. Environment Oxygen at Altitude and in Aircraft 712

III. Physiological Consequences of Air Travel 713

IV. Risks of Air Travel 715

V. Assessment of In-Flight Oxygenation 719

VI. Fitness to Fly and Oxygen Supplementation 722

VII. Practical Considerations 723

VIII. Future Directions 725

21. Advanced Lung Disease: End-of-Life Care / John Hansen-Flaschen 731

II. Attributes of a Good Death 732

III. Prognosis 732

IV. Advance Medical Planning 736

V. Hospice Home Care 739

VI. Dying at Home 742.

Notes:

Includes bibliographical references and index.

ISBN:

0824740777

OCLC:

52159369